TherapeuticsMD, Inc.: directors' dealings · United States · SEC (Form 4)

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a United States-based women’s health pharmaceutical company listed on the NASDAQ under the ticker TXMD. From an investor’s perspective, it is no longer a conventional fully integrated drug developer; the company now describes itself as a royalty company that licenses differentiated women’s health products in the United States and internationally through exclusive partners. Its strategic focus remains tightly concentrated on women’s health, particularly family planning, reproductive health, and menopause management. ([therapeuticsmd.com](https://www.therapeuticsmd.com/)) The company was founded around the idea of addressing underserved needs across the different stages of women’s lives. Over time, its business model has evolved materially, and the latest SEC filings show that the group is organized as a Nevada corporation with principal executive offices at 951 Yamato Road, Suite 220, Boca Raton, Florida. The 10-K also states that TherapeuticsMD operates in a fully remote environment and has subleased all of its Boca Raton premises following the shift toward a pharmaceutical royalty model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000025743/000121390026036515/ea0275992-10k_therape.htm)) TherapeuticsMD’s branded portfolio has included ANNOVERA®, BIJUVA® and IMVEXXY®, which are central to its women’s health platform. The company emphasizes that these products are licensed in the U.S. and the rest of the world to exclusive licensing partners, so the economic engine is based primarily on intellectual property, licensing arrangements, and partner commercialization rather than on a large in-house sales infrastructure. That structure can be capital-light relative to traditional pharma, but it also means the company is highly dependent on third parties for manufacturing, commercialization, reimbursement dynamics, and execution. ([therapeuticsmd.com](https://www.therapeuticsmd.com/)) In competitive terms, TXMD sits in a crowded segment where branded women’s health products compete against generics, alternative therapies, and larger pharmaceutical companies with deeper resources. The latest annual report highlights several key risk vectors: disputes with Mayne Pharma, the ability of licensees to commercialize licensed products successfully, regulatory and reimbursement pressure, and uncertainty around the company’s ability to continue as a going concern. These are important for equity investors because they indicate that the stock is driven as much by legal and financial developments as by product demand. ([ir.therapeuticsmd.com](https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-full-year-2025-financial-results)) Recent developments remain shaped by the transition story. On March 30, 2026, TherapeuticsMD reported full-year 2025 results, stating that license revenue increased year over year to $3.0 million while the net loss from continuing operations improved versus 2024. At the same time, management continued to flag substantial doubt about the company’s ability to continue as a going concern and ongoing litigation-related issues. For investors tracking U.S.-listed healthcare special situations, TXMD is best viewed as a small-cap royalty and litigation-sensitive name rather than a traditional growth pharma platform. ([ir.therapeuticsmd.com](https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-full-year-2025-financial-results))